JPRN-UMIN000001631已完成2 期
Phase II study of a combination of CPT-11 and S-1 and bevacizumab in patients with metastatic colon cancer. - Phase II study of a combination of CPT-11 and S-1 and bevacizumab in patients with metastatic colon cancer.
iigata Colorectal cancer Chemotherapy Study Group (NCCSG)0 个研究点目标入组 35 人开始时间: 2009年1月14日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The exclusion criteria were as follows; patients were not eligible for this study if; 1) they had undergone treatment with CPT-11 chemotherapy prior to this study, 2) had active double cancer; 3) had active infection disease (over 38.0C fever); 4) had gastrointestinal paralysis, bowel blockage or history within 1 year before entry; 5) had serious interstitial lung disease and lung fibrosis; 6) had water solubility diarrhea; 7) had diabetes mellitus which could not be controlled; 8) had hypertension which could not control with drug therapy; 9) had proteinuria > 2 plus 10) had serious complication (e.g. heart failure, hepatic failure, kidney failure); 11) had comorbid disease of cerebral vascular disorder or history within 1 year before entry; 12) were operated or performed dissected biopsy within 4 weeks before entry; 13) were bleeding tendency, coagulation disorder, abnormality of coagulation factor (INR>1.5) within 2 weeks before entry; 14) were administered antithrombotic within 10 days before entry; 15) were administered antiplatelet agent for chronic rheumatoid arthritis; 16) were administred flucytosine or atazanavir ; 17) were systemically-administered of steroids ; 18) Pregnant or lactating women, women who are capable of pregnancy or intend to get pregnant ; 19) had a previous serious medical illness or allergy for drugs ; 20) had brain metastasis or had treated for brain metastasis ; 21) had myelosuppression ; 22) had pleural effusion or abdominal dropsy which need therapy ; 23) had jaundice ; 24) except referred to above, physician in charge of this trial gave a diagnosis the patient who can not joint this trail for the safety.
研究者
相似试验
已完成
2 期
Phase II study of a combination of CPT-11 and S-1 and Panitumumab in patients with KRAS wild-type metastatic colon cancer.KRAS wild-type metastatic colon cancer.JPRN-UMIN000005368iigata Colorectal cancer Chemotherapy Study Group (NCCSG)25
已完成
不适用
Phase II study of Combination of CPT-11 and S-1 for Advanced Non-Small-cell lung cancerPreviously untreated stageIIIB/IV NSCLCJPRN-C000000415West Japan Oncology Group55
未知
1 期
Phase1study of a combination of CPT-11 and TS-1 and bevacizumab in patients with metastatic colon cancermetastatic colorectal cancerJPRN-UMIN000001219Department of Surgery, Suita Municipal Hospital24
已完成
2 期
Phase II study of a combination of modified CPT-11 and 5-FU/l-LV (mJIFL) in patients with meatastatic colorectal cancerMeatastatic colorectal cancerJPRN-UMIN000000727OGSG54
招募中
不适用
Randomized phase II study of CPT-11 plus TS-1 plus Cetuximab for advanced and/or recurrent colon cancer which are oxaliplatin-resistant and KRAS wild type (OGSG 0901)advanced and/or recurrent colon cancer which are oxaliplatin-resistant and KRAS wild typeJPRN-UMIN000002695Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)35